OPEN

Pneumoconiosis Increases the Risk of Peripheral Arterial Disease
A Nationwide Population-Based Study
Chih-Hao Shen, MD, Te-Yu Lin, MD, Wen-Yen Huang, MD, Hsuan-Ju Chen, MSc, and Chia-Hung Kao, MD

Abstract: This nationwide population-based retrospective cohort study was used to evaluate the association between pneumoconiosis and peripheral arterial disease (PAD).

We identified 3374 patients with pneumoconiosis from the catastrophic illness registry who were newly diagnosed from 2000 to 2005; 13,496 patients without pneumoconiosis from Longitudinal Health Insurance Database 2000 (LHID2000) were randomly frequency matched according to sex, age, and index year and used as a nonpneumoconiosis group. Multivariate Cox proportional hazards regression was used to calculate adjusted hazard ratios (HRs) of PAD in the pneumoconiosis group compared with the nonpneumoconiosis group.

The mean follow-up years were 7.44 years in the pneumoconiosis group and 8.17 years in the nonpneumoconiosis group. The incidence density rate of PAD was 1.25 times greater in the pneumoconiosis group than in the nonpneumoconiosis group (8.37 vs 6.70 per 1000 person-years). After adjusting for sex, age, and comorbidities, the adjusted HRs of PAD for the pneumoconiosis group were 1.30 (95% CI = 1.08–1.57), compared with the nonpneumoconiosis group. The combined impacts of patients with pneumoconiosis and diabetes, hyperlipidemia, hypertension, ischemic heart disease, chronic obstructive pulmonary disease, and asthma showed a significant joint association with PAD risk compared with patients with no pneumoconiosis and no counterpart comorbidity.

Patients with pneumoconiosis have an independently higher risk of developing PAD. Physicians should include pneumoconiosis in evaluating PAD risk.

(INTRODUCTION)

Pneumoconiosis is a group of occupational lung diseases associated with the inhalation of mineral dusts and reaction of lung tissue to them, which eventually induce irreversible lung damage.1 The Global Burden of Disease Study disclosed that approximately 125,000 deaths per year resulted from pneumoconiosis as of 2010.2 In the United States, pneumoconiosis resulted in 1000 to 2000 hospitalizations per year and accounted for 525 deaths in 2007.3 The principal cause of pneumoconiosis is workplace exposure, mostly exposure to inorganic mineral particles such as coal dust, crystalline silica, and asbestos. Pathologic features of pneumoconiosis include focal collections of dust and reticulin around the small airways, fibrotic lesions exhibiting irregularly arranged collagen, and lesions of massive fibrosis.4,5 An inflammatory cascade including direct oxidant effects, alveolar macrophages activation, and then alveolar epithelial cell damage is triggered through exposure.6,6 Several cytokines, such as tumor necrosis factor-α, interleukin-1, platelet-derived growth factor, transforming growth factor-β, and interleukin-6, play crucial roles in recruiting inflammatory cells into the alveoli and producing this chronic inflammation.6,7

Peripheral arterial disease (PAD), which is caused by atherosclerosis and thromboembolic pathophysiologic processes that alter the arteries of the lower extremity, affects about 27 million individuals in Europe and North America.8,9 The worldwide prevalence of PAD ranges from 2.35% to 12%.8,10–14 PAD is underdiagnosed and undertreated but causes a considerable burden to health care systems.15,16 The common risk factors associated with developing PAD are increased age,
female sex, smoking, diabetes, and hyperlipidemia.\textsuperscript{14,17–20} Diseases such as hypertension, ischemic heart disease (IHD), heart failure, stroke, chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD) have been well established as playing major roles in the pathogenesis of PAD or its clinical manifestations.\textsuperscript{20–26}

Multiple, independent pathways of evidence have pinpointed inflammation as a main regulatory process for atherosclerosis in various arterial beds, including that in PAD.\textsuperscript{27,28} Pneumoconiosis commonly represents chronic inflammation, but previous studies on the association between pneumoconiosis and PAD have been few. We conducted a nationwide population-based cohort study to investigate whether pneumoconiosis increases the risk of PAD.

METHODS

Data Source
Taiwan’s National Health Insurance (NHI) program was implemented in 1995 and offers comprehensive medical coverage to all residents of Taiwan. The National Health Research Institute of the Ministry of Health and Welfare maintains and releases the National Health Insurance Research Database (NHIRD) for use in health service studies. Comprehensive information on insured NHI participants is included in the database, including patients’ sex and date of birth, all records of clinical visits and hospitalizations, prescribed drugs and dosages, and diagnosed diseases. The diagnostic codes used are based on the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The NHIRD covers a highly representative sample of Taiwan’s general population because the reimbursement policy is universal and operated by a single buyer, the government in Taiwan. All insurance claims should be scrutinized by medical reimbursement specialists and peer review.

In this study, we used data sets of the Registry for LHID2000 and Catastrophic Illness Patient Database. Every individual in Taiwan has a unique personal identification number. The anonymity of those insured is retained by cryptographically scrambling their personal data. All NHI data sets can be interlinked with the personal identification number of each individual. This study was approved by the Institutional Review Board of China Medical University in Central Taiwan (CMU-REC-101-012).

Population
We conducted a nationwide population-based cohort that included 2 groups. The case group was defined as newly diagnosed patients with pneumoconiosis (ICD-9-CM codes 500, 501, 502, 503, and 505) with a certificate of catastrophic illness between 2000 and 2005. In Taiwan, pneumoconiosis is one of 30 major categories of conditions recognized as catastrophic illnesses and covered under the NHI program. The application date of the catastrophic illness certificate was used as the index date. Patients with PAD before the index date and those with incomplete information (ie, age or sex) were excluded from this study. For each patient with pneumoconiosis, 4 study participants were randomly selected from the LHID2000 without a history of pneumoconiosis or PAD and frequency matched using a sex, 5-year age interval, and the year of the index date.

The demographic factors in this study included sex and age (in groups aged 20–64 and ≥65 years). We considered diabetes (ICD-9-CM code 250), hyperlipidemia (ICD-9-CM code 272), hypertension (ICD-9-CM codes 401–405), IHD (ICD-9-CM codes 410–414), heart failure (ICD-9-CM code 428), stroke (ICD-9-CM codes 430–438), COPD (ICD-9-CM codes 490, 491, 495, and 496), and CKD (ICD-9-CM code 585) as comorbidities that could potentially confound the association between pneumoconiosis and PAD. Smoking is a risk factor for PAD, and smokers have an increased risk of IHD, stroke, COPD, and asthma. Because history of smoking was not available in the database of Taiwan NHI, adjustment of the data with smoking-related disorders such as stroke, IHD, COPD, and asthma (ICD-9-CM code 493) contributes to minimize confounding from the effect of smoking.\textsuperscript{29} PAD was diagnosed and coded (ICD-9-CM codes 440.0, 440.2, 440.3, 440.8, 440.9, 443, 444.0, 444.2, 444.8, 447.8, and 447.9) by the specialists according to the standard diagnosed criteria including typical symptoms/signs, laboratory data, and imaging findings. Occurrences of PAD were determined from NHIRD ambulatory and inpatient care records. All patients were observed from the index date to the PAD diagnosis date, withdrawal from the NHI program, or the end of 2011.

Statistical Analysis
Summary statistics are expressed as frequencies and percentages for categorical data and means ± standard deviations (SD) for continuous variables, as appropriate. Pearson $\chi^2$ tests and Student t tests were used to compare categorical and continuous variables between patients with and without pneumoconiosis, respectively. Follow-up time in person-years was calculated for each person until PAD diagnosis, death, cancellation of follow-up, or completion of follow-up (December 31, 2011). Incidence density rates were calculated by dividing the number of participants newly diagnosed with PAD by the number of person-years for each group by sex, age, and comorbidity. A Kaplan–Meier analysis was used to calculate the cumulative incidence rates of PAD in the groups of participants with and without pneumoconiosis, and a log-rank test was employed to analyze differences between the survival curves. We performed a Cox proportional hazards analysis stratified by sex, age group, and comorbidity to examine the effect of pneumoconiosis when manually adjusting for sex, age, and comorbidity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to quantify the risk of PAD. SAS Version 9.3 software (SAS Institute, Cary, NC) was used for data analyses; 2-sided tests were performed, and $P < .05$ was considered statistically significant.

RESULTS
We identified 3374 patients with pneumoconiosis from 2000 to 2005 and assigned them to the pneumoconiosis group and frequency matched 13496 participants without pneumoconiosis by sex and age and assigned them to the nonpneumoconiosis group. The distribution of sex and age were similar in both groups. Patients with pneumoconiosis had a lower prevalence of diabetes and a higher prevalence of IHD, heart failure, asthma, and COPD than those of patients without pneumoconiosis (Table 1). The mean follow-up years were 7.44 (SD = 3.59 years) in the pneumoconiosis group and 8.17 (SD = 3.16 years) in the nonpneumoconiosis group.

Patients with pneumoconiosis had a higher risk of PAD than those of patients without pneumoconiosis (adjusted HR = 1.30, 95% CI = 1.08–1.57) in the multivariate Cox model (Table 2).

Furthermore, each 1-year increment in age had an
TABLE 1. Baseline Demographic Factors and Comorbidity of Study Participants According to Pneumoconiosis Status

| Variables | Nonpneumoconiosis N = 13496 | Pneumoconiosis N = 3374 | P  |
|-----------|-----------------------------|--------------------------|----|
| Sex       | n  | %        | n  | %        |  |
| Female    | 2448 | 18.14 | 612 | 18.174 | 0.98 |
| Male      | 11048 | 81.86 | 2762 | 81.86 |  |
| Age, y    | 0.99 |
| 20–64     | 5616 | 41.61 | 1404 | 41.61 |  |
| ≥65       | 7880 | 58.39 | 1970 | 58.39 | |
| Mean (SD) | 66.54 (8.34) | 66.88 (7.86) | 0.03 |
| Comorbidity | | | | |
| Diabetes  | 2197 | 16.28 | 460 | 13.63 | <0.001 |
| Hyperlipidemia | 2946 | 21.83 | 690 | 20.45 | 0.09 |
| Hypertension | 6541 | 48.47 | 1652 | 48.96 | 0.62 |
| IHD       | 3339 | 24.74 | 960 | 28.45 | <0.001 |
| Heart failure | 514 | 3.81 | 231 | 6.85 | <0.001 |
| Stroke    | 782 | 5.79 | 215 | 6.37 | 0.22 |
| COPD      | 732 | 5.42 | 2080 | 61.65 | <0.001 |
| Asthma    | 1009 | 7.48 | 1023 | 30.32 | <0.001 |
| CKD       | 268 | 1.99 | 58 | 1.72 | 0.35 |

CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, IHD = ischemic heart disease, SD = standard deviation.

increased risk of PAD (adjusted HR = 1.03, 95% CI = 1.02–1.04). Patients with diabetes, hyperlipidemia, hypertension, or IHD had a significantly higher risk of PAD than did those without these diseases (adjusted HR = 1.38, 95% CI = 1.17–1.62; 1.26, 1.08–1.46; 1.28, 1.11–1.49; and 1.38, 1.19–1.60, respectively).

Figure 1 presents the cumulative-incidence curves of PAD according to pneumoconiosis status. We used the log-rank test to compare the cumulative incidence of PAD in the 2 groups, determining that the cumulative incidence of PAD was significantly higher in patients with pneumoconiosis than in those without pneumoconiosis (P < .01).

Table 3 shows the incidence density rates and HRs of PAD according to pneumoconiosis status stratified by demographic factors and comorbidity. Patients with pneumoconiosis had a higher incidence of PAD than did those without pneumoconiosis (8.37 vs 6.70 per 1000 person-years). Sex-specific analysis indicated that the incidence density rates of PAD in females and males with pneumoconiosis were 9.94 and 7.95 per 1000 person-years, respectively; these rates were higher than those in patients without pneumoconiosis (7.74 and 6.42 per 1000 person-years, respectively). In addition, males in the pneumoconiosis group showed a 1.36-fold (adjusted HR = 1.36, 95% CI = 1.09–1.70) higher risk of PAD than those in the nonpneumoconiosis group. Compared with patients without pneumoconiosis, patients with pneumoconiosis had a higher adjusted HR of PAD in aged 20 to 64 years (adjusted HR = 1.59, 95% CI = 1.16–2.18). In individuals without comorbidity and in the subgroup without diabetes, hyperlipidemia, hypertension, IHD, heart failure, stroke, or CKD, patients with pneumoconiosis were more likely to have PAD than those without pneumoconiosis (adjusted HR = 1.73, 95% CI = 1.15–2.60; 1.33, 1.07–1.64; 1.34, 1.07–1.67; 1.66, 1.24–2.22; 1.52, 1.21–1.92; 1.32, 1.08–1.60; 1.36, 1.12–1.65; and 1.30, 1.08–1.58, respectively). In individuals with asthma, patients with pneumoconiosis were more likely to have PAD than those without pneumoconiosis (adjusted HR = 1.67, 95% CI = 1.02–2.71) (Table 3).

Table 4 shows the combined effect of pneumoconiosis and the comorbidities of diabetes, hyperlipidemia, hypertension, IHD, heart failure, stroke, COPD, asthma, and CKD on the risk of PAD in relation to the referent group of no pneumoconiosis and no comorbidities. We observed a greater magnitude

TABLE 2. Univariate and Multivariate Analyses for Predicting Peripheral Arterial Disease Risk

| Variables | Univariate HR (95% CI) | Multivariate $^*$ HR (95% CI) |
|-----------|------------------------|-------------------------------|
| Pneumoconiosis | | |
| No | 1.00 | 1.00 |
| Yes | 1.25 (1.07–1.45)** | 1.30 (1.08–1.57)** |
| Sex | | |
| Female | 1.00 | 1.00 |
| Male | 0.82 (0.70–0.95)** | 0.91 (0.78–1.06)*** |
| Age (each increment year) | | |
| No | 1.00 | 1.00 |
| Yes | 1.04 (1.03–1.05)** | 1.03 (1.02–1.04)*** |
| Comorbidity | | |
| Diabetes | | |
| No | 1.00 | 1.00 |
| Yes | 1.75 (1.50–2.04)*** | 1.38 (1.17–1.62)*** |
| Hyperlipidemia | | |
| No | 1.00 | 1.00 |
| Yes | 1.62 (1.41–1.85)*** | 1.26 (1.08–1.46)*** |
| Hypertension | | |
| No | 1.00 | 1.00 |
| Yes | 1.77 (1.56–2.02)*** | 1.28 (1.11–1.49)*** |
| IHD | | |
| No | 1.00 | 1.00 |
| Yes | 1.87 (1.64–2.13)*** | 1.38 (1.19–1.60)*** |
| Heart failure | | |
| No | 1.00 | 1.00 |
| Yes | 1.70 (1.29–2.24)*** | 1.08 (0.81–1.44) |
| Stroke | | |
| No | 1.00 | 1.00 |
| Yes | 1.29 (0.98–1.70) | 0.93 (0.71–1.24) |
| COPD | | |
| No | 1.00 | 1.00 |
| Yes | 1.18 (0.99–1.41) | 0.88 (0.71–1.10) |
| Asthma | | |
| No | 1.00 | 1.00 |
| Yes | 1.32 (1.09–1.59)** | 1.08 (0.88–1.33) |
| CKD | | |
| No | 1.00 | 1.00 |
| Yes | 1.91 (1.29–2.82)** | 1.37 (0.93–2.04) |

CI = confidence interval, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, HR = hazard ratio, IHD = ischemic heart disease.

$^*$Multivariable analysis including pneumoconiosis, sex, age, diabetes, hyperlipidemia, hypertension, ischemic heart disease, heart failure, stroke, chronic obstructive pulmonary disease, asthma, and chronic kidney disease.

**P < 0.01.

***P < 0.001.
of HRs of PAD for patients with pneumoconiosis and diabetes, hyperlipidemia, hypertension, IHD, COPD, and asthma compared with patients with no pneumoconiosis and no counterpart comorbidity (adjusted HR = 2.00, 95% CI = 1.44–2.78; 1.74, 1.32–2.31; 1.81, 1.45–2.26; 1.67, 1.29–2.15; 1.25, 1.04–1.52; and 1.42, 1.09–1.83, respectively).

**DISCUSSION**

This is the first nationwide population-based cohort study to investigate the associations between pneumoconiosis and PAD. After adjustments for sex, age, diabetes, hyperlipidemia, hypertension, IHD, heart failure, stroke, COPD, asthma, and CKD, a Cox proportional hazard model showed that patients with pneumoconiosis had a 1.30-fold higher risk of developing PAD compared with those without pneumoconiosis.

Although the patients with pneumoconiosis in this study exhibited a difference in prevalence of comorbidities associated with PAD development (such as diabetes, IHD, heart failure, and COPD) than did the comparison cohort, pneumoconiosis remained an independent factor in multivariate Cox analyses for predicting PAD risk. In addition to pneumoconiosis, our data also indicate that increased age, diabetes, hyperlipidemia, hypertension, and IHD are independent risk factors for PAD, which was compatible with the current consensus regarding risk factors for PAD.17–20 Comparably, we found that patients with pneumoconiosis had a significantly higher PAD incidence than did those without pneumoconiosis in the subgroup of male sex, younger than 65 years, and no comorbidity (Table 3). These findings were contrary to the current consensus but strengthened the observation that pneumoconiosis influences PAD independently.

Most previous studies on pneumoconiosis have focused on its pulmonary manifestations such as interstitial lung disease, pulmonary fibrosis, and COPD.5 Vascular injury associated with pneumoconiosis has been less frequently described. Lee et al evaluated the coronary artery calcification (which correlated with the degree of atherosclerosis) of 76 patients exposed to inorganic dusts by using multidetector computed tomography, which disclosed that patients with pneumoconiosis had a higher frequency in the calcified group than in the noncalcified group.20 An inverse relationship was found between restrictive lung disease and atherosclerosis risk in workers exposed to inorganic dust.31 Additional research is urgent to determine the inflammatory response of pneumoconiosis and its role in the course of atherosclerosis and PAD development.

Thromboembolic processes may also be involved in the development of PAD caused by pneumoconiosis. In an animal model, intratracheally instilled silica particles enhanced pulmonary macrophage-neutrophil cross-talk, released neutrophil elastase into the blood circulation, triggered activation of circulating platelets, and then initiated thrombin and eventually damaged peripheral vasculature.32 Pulmonary inflammation induced by carbon nanotubes translated rapid and transient activation of platelets into P-selectin-mediated systemic inflammation, eliciting in turn prothrombotic risk.33 Our data indicate that male sex, younger than 65 years, and no comorbidity were associated with higher PAD incidence when comparing the pneumoconiosis and nonpneumoconiosis cohorts. Although older participants may have experienced longer occupational exposure with the accumulated effects of chronic inflammation, young male participants without comorbidity may have experienced greater workloads and more occupational exposures within the follow-up period. We propose the hypothesis that acute or subacute thromboembolic events coexist with the atherosclerosis to develop PAD in patients with pneumoconiosis.

The risk of developing PAD for patients afflicted with pneumoconiosis and diabetes, hyperlipidemia, hypertension, IHD, or COPD was higher than for those without pneumoconiosis and their corresponding comorbidities. However, we observed that only patients with pneumoconiosis who exhibited diabetes, hyperlipidemia, hypertension, or COPD had significantly increased multiplicative risks of PAD. The increased effect on multiplicative risk of PAD in patients with pneumoconiosis who exhibited IHD was equivocal. Otherwise, CKD and stroke, though nonspecific, were found to reduce the effect of increasing risk of PAD for patients with pneumoconiosis (Table 4). IHD, stroke, CKD, and PAD have similar pathological implications for arteries; thus, antiplatelet therapy is universal for daily prevention. A previous study showed that atherosclerotic risk factors were less intensively treated among PAD patients than among IHD patients.13 Providing adequate care for patients with pneumoconiosis with these comorbidities may be crucial in preventing further development of PAD.

This study had several limitations. First, the NHIRD lacks information on patient behaviors and about certain critical cardiovascular risk factors such as smoking, obesity and BMI, alcoholism, exercise, and dietary habits. Second, we could not assess exposure periods and dust concentrations or the severity of pneumoconiosis (such as the extent of pulmonary fibrosis and decline of ventilator function) of the patients. These data are not contained in the NHIRD; thus, future studies are warranted. Third, it is difficult to do subgroup analyses because there are few cases in some of the following codes (ICD-9-CM codes: 501, 502, 503) (Supplementary Table, http://links.lww.com/MD/A285). Finally, an analysis of PAD prophylaxis patterns, a confounding factor that may have affected the outcome measurements, was infeasible in this study. The evidence derived from a retrospective cohort study is generally lower in statistical quality than that obtained from randomized trials because of potential biases related to adjustments for...
confounding variables. We have included hypertension, diabetes, and hyperlipidemia to adjust for the influence of BMI and obesity. To minimize the potential confounding effect of smoking, an alternative method to adjust for smoking-related diseases (including IHD, COPD, asthma, and stroke) in analysis was used, which was used in a previous study. However, bias resulting from unknown confounders may have affected the results despite our meticulous study design and control measures for confounding factors.

In conclusion, this study demonstrated that the patients with pneumoconiosis exhibited a 1.30-fold risk of developing PAD compared with the general population by using a nationwide population-based database that contains a relatively high number of pneumoconiosis cases. In addition to the consensus

TABLE 3. Incidence Density Rates and Hazard Ratios of Peripheral Arterial Disease According to Pneumoconiosis Status Stratified by Demographic Factors and Comorbidity

| Variables                  | Pneumoconiosis | Compared to Nonpneumoconiosis Group |
|----------------------------|----------------|------------------------------------|
|                            | No             | Yes                                |                                  |
|                            | Event No.      | Person-Years IR                    | Event No. | Person-Years IR | Crude HR (95% CI) | Adjusted* HR (95% CI) |
| Overall                    | 739            | 110315.36                           | 210       | 25102.78        | 1.25 (1.07–1.45)** | 1.30 (1.08–1.57)** |
| Sex                        |                |                                    |           |                 |                     |                     |
| Female                     | 164            | 21181.48                            | 52        | 5231.07         | 1.28 (0.94–1.75)   | 1.22 (0.85–1.74)   |
| Male                       | 575            | 89133.89                            | 158       | 19871.70        | 1.23 (1.03–1.47)** | 1.36 (1.09–1.70)** |
| Age, y                     |                |                                    |           |                 |                     |                     |
| 20–64                      | 246            | 50430.72                            | 87        | 11400.42        | 1.57 (1.23–2.00)** | 1.59 (1.16–2.18)** |
| ≥ 65                       | 493            | 59884.65                            | 123       | 13702.36        | 1.09 (0.89–1.33)   | 1.13 (0.89–1.44)   |
| Comorbidity†               |                |                                    |           |                 |                     |                     |
| No                         | 166            | 45615.90                            | 31        | 4410.13         | 1.89 (1.26–2.84)** | 1.73 (1.15–2.60)** |
| Yes                        | 573            | 64699.47                            | 179       | 20692.65        | 0.98 (0.83–1.16)   | 1.01 (0.86–1.20)   |
| Diabetes                   |                |                                    |           |                 |                     |                     |
| No                         | 565            | 94339.50                            | 172       | 22078.56        | 1.30 (1.10–1.54)** | 1.33 (1.07–1.64)** |
| Yes                        | 174            | 15975.87                            | 38        | 3024.22         | 1.15 (0.81–1.63)   | 1.19 (0.78–1.82)   |
| Hyperlipidemia             |                |                                    |           |                 |                     |                     |
| No                         | 502            | 86531.97                            | 156       | 19824.70        | 1.36 (1.13–1.62)** | 1.34 (1.07–1.67)*  |
| Yes                        | 237            | 23738.39                            | 179       | 20692.65        | 1.02 (0.76–1.37)   | 1.20 (0.84–1.72)   |
| Hypertension               |                |                                    |           |                 |                     |                     |
| No                         | 274            | 59554.64                            | 100       | 13114.45        | 1.66 (1.32–2.09)** | 1.66 (1.24–2.22)** |
| Yes                        | 465            | 50760.73                            | 110       | 11988.33        | 0.99 (0.81–1.23)   | 1.08 (0.84–1.39)   |
| IHD                        |                |                                    |           |                 |                     |                     |
| No                         | 456            | 84911.38                            | 141       | 18123.38        | 1.45 (1.20–1.75)** | 1.52 (1.21–1.92)** |
| Yes                        | 283            | 25403.98                            | 69        | 6979.40         | 0.88 (0.68–1.15)   | 0.96 (0.69–1.33)   |
| Heart failure              |                |                                    |           |                 |                     |                     |
| No                         | 701            | 107099.52                           | 194       | 23729.51        | 1.25 (1.06–1.46)** | 1.32 (1.08–1.60)** |
| Yes                        | 38             | 3215.85                             | 16        | 1373.26         | 0.99 (0.55–1.77)   | 0.98 (0.45–2.16)   |
| Stroke                     |                |                                    |           |                 |                     |                     |
| No                         | 694            | 105598.19                           | 202       | 23962.23        | 1.28 (1.10–1.50)** | 1.36 (1.12–1.65)** |
| Yes                        | 45             | 4717.17                             | 8         | 1140.55         | 0.73 (0.35–1.55)   | 0.60 (0.24–1.46)   |
| COPD                       |                |                                    |           |                 |                     |                     |
| No                         | 706            | 105597.60                           | 87        | 10654.31        | 1.23 (0.98–1.53)   | 1.22 (0.98–1.53)   |
| Yes                        | 33             | 4717.77                             | 123       | 14448.47        | 1.22 (0.83–1.79)   | 1.40 (0.94–2.10)   |
| Asthma                     |                |                                    |           |                 |                     |                     |
| No                         | 678            | 103158.85                           | 147       | 18481.30        | 1.21 (1.01–1.45)*  | 1.23 (0.99–1.51)   |
| Yes                        | 61             | 7156.51                             | 63        | 6621.48         | 1.10 (0.78–1.57)   | 1.67 (1.02–2.71)*  |
| CKD                        |                |                                    |           |                 |                     |                     |
| No                         | 715            | 108720.32                           | 208       | 24756.98        | 1.28 (1.09–1.49)** | 1.30 (1.08–1.58)** |
| Yes                        | 24             | 1595.04                             | 2         | 345.80          | 0.38 (0.09–1.61)   | 0.84 (0.18–3.87)   |

CI = confidence interval, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, HR = hazard ratio, IHD = ischemic heart disease, IR = incidence density rate, per 1000 person-years.

* Mutually adjusted for sex, age, and comorbidity in Cox proportional hazards regression.

† Patients with any one of diabetes, hyperlipidemia, hypertension, ischemic heart disease, heart failure, stroke, chronic obstructive pulmonary disease, asthma, and chronic kidney disease were classified as the comorbidity group.

P < 0.05.

** P < 0.01.

*** P < 0.001.
that the development of PAD is mainly associated with atherosclerosis, we propose the hypothesis that a coexistence of thromboembolic events may also aggravate the PAD risk in patients with pneumoconiosis. Physicians should consider the possibility of PAD when following up patients with pneumoconiosis and should include pneumoconiosis in evaluating PAD risk.

### REFERENCES

1. Fourth International Pneumoconiosis Conference. Report of the Working Party on the Definition of Pneumoconiosis. Geneva, Switzerland: International Labour Organization 1971.

2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):2095–2128.

### TABLE 4. Interaction and Joint Effect Between Pneumoconiosis and Comorbidity in Association With Peripheral Arterial Disease in Study Population

| Variables          | Diabetes | HR† (95% CI) | p for interaction |
|--------------------|----------|--------------|-------------------|
| Pneumoconiosis     | Diabetes | HR† (95% CI) | p for interaction |
| No                 | No       | 1.00         | 0.63              |
| No                 | Yes      | 1.71 (1.44–2.03)*** | 0.18              |
| Yes                | No       | 1.28 (1.08–1.52)**   | 0.18              |
| Yes                | Yes      | 2.00 (1.44–2.78)*** | 0.18              |
| Hyperlipidemia     | Hyperlipidemia | 1.68 (1.44–1.96)*** | 0.18              |
| Yes                | No       | 1.34 (1.12–1.60)**   | 0.18              |
| Yes                | Yes      | 1.74 (1.32–2.31)*** | 0.18              |
| Hypertension       | Hypertension | 1.77 (1.52–2.06)*** | 0.18              |
| Yes                | No       | 1.60 (1.27–2.02)*** | 0.18              |
| Yes                | Yes      | 1.81 (1.45–2.26)*** | 0.18              |
| IHD                | IHD      | 1.84 (1.58–2.14)*** | 0.18              |
| Yes                | No       | 1.43 (1.18–1.73)*** | 0.18              |
| Yes                | Yes      | 1.67 (1.29–2.15)*** | 0.18              |
| Heart failure      | Heart failure | 1.52 (1.09–2.11)*   | 0.18              |
| Yes                | No       | 1.24 (1.06–1.45)**   | 0.18              |
| Yes                | Yes      | 1.56 (0.95–2.56)     | 0.18              |
| Stroke             | Stroke   | 1.27 (0.94–1.72)**   | 0.18              |
| Yes                | No       | 1.27 (1.09–1.48)**   | 0.18              |
| Yes                | Yes      | 0.95 (0.47–1.90)     | 0.18              |
| COPD               | COPD     | 0.89 (0.62–1.26)     | 0.18              |
| Yes                | No       | 1.20 (0.96–1.50)*    | 0.18              |
| Yes                | Yes      | 1.25 (1.04–1.52)*    | 0.18              |
| Asthma             | Asthma   | 1.16 (0.89–1.51)     | 0.18              |
| Yes                | No       | 1.19 (0.99–1.42)**   | 0.18              |
| Yes                | Yes      | 1.42 (1.09–1.83)**   | 0.18              |
| CKD                | CKD      | 2.05 (1.36–3.08)***  | 0.18              |
| Yes                | No       | 1.26 (1.08–1.48)**   | 0.18              |
| Yes                | Yes      | 0.82 (0.20–3.27)     | 0.18              |

CI = confidence interval, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, HR = hazard ratio, IHD = ischemic heart disease.

†Model adjusted for sex and age.

* P < 0.05.

** P < 0.01.

*** P < 0.001.
2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380:2095–2128.

3. Laney AS, Weissman DN. The classic pneumoconioses: new epidemiological and laboratory observations. *Clin Chest Med.* 2012;33:745–758.

4. Castranova V, Vallyathan V. Silicosis and coal workers’ pneumoconiosis. *Environ Health Perspect.* 2000;108(Suppl 4):675–684.

5. Cohen RA, Patel A, Green FH. Lung disease caused by exposure to coal mine and silica dust. *Semin Respir Crit Care Med.* 2008;29:651–661.

6. Fujimura N. Pathology and pathophysiology of pneumoconiosis. *Curr Opin Pulm Med.* 2000;6:140–144.

7. Yucseso B, Vallyathan V, Landsittel DP, et al. Cytokine polymorphisms in silicosis and other pneumoconioses. *Mol Cell Biochem.* 2002;234–235:219–224.

8. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol.* 2006;47:1239–1312.

9. 2011 WRITING GROUP MEMBERS; 2005 WRITING COMMITTEE MEMBERS; ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation.* 2011;124:2020–2045.

10. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. *Circulation.* 2004;110:738–743.

11. Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. *J Vasc Surg.* 2014;60:686–695.e682.

12. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. *N Engl J Med.* 2001;344:1608–1621.

13. McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. *J Gen Intern Med.* 1997;12:209–215.

14. Chen YJ, Lin MS, Hsu KY, et al. Prevalence of asymptomatic peripheral arterial disease and related risk factors in younger and elderly patients in Taiwan. *Angiology.* 2014;65:396–401.

15. Chang NT, Chan CL, Lu YT, et al. Invasively-treated incidence of lower extremity peripheral arterial disease and associated factors in Taiwan: 2000–2011 nationwide hospitalized data analysis. *BMC Public Health.* 2013;13:1107.

16. Jaff MR, Cahill KE, Yu AP, et al. Clinical outcomes and medical care costs among medicare beneficiaries receiving therapy for peripheral arterial disease. *Ann Vasc Surg.* 2010;24:577–587.

17. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). *J Vasc Surg.* 2007;45(Suppl S):S5–S67.

18. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. *Circulation.* 1995;91:1472–1479.

19. Hiramoto JS, Katz R, Weismann S, et al. Gender-specific risk factors for peripheral artery disease in a voluntary screening population. *J Am Heart Assoc.* 2014;3:e000651.

20. Eraso LH, Fukaya E, Mohler ER, et al. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. *Eur J Prev Cardiol.* 2012;21:704–711.

21. Cacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *Atherosclerosis.* 2009;204:e86–e92.

22. Olin JW. Hypertension and peripheral arterial disease. *Vasc Med.* 2005;10:241–246.

23. Chen J, Mohler ER, Xie D, et al. Risk factors for peripheral arterial disease among patients with chronic kidney disease. *Am J Cardiol.* 2012;110:136–141.

24. Lin MS, Hsu KY, Chen YJ, et al. Prevalence and risk factors of asymptomatic peripheral arterial disease in patients with COPD in Taiwan. *PLoS One.* 2013;8:e64714.

25. O’Neal WT, Efird JT, Nazarian S, et al. Peripheral arterial disease and risk of atrial fibrillation and stroke: the multi-ethnic study of atherosclerosis. *J Am Heart Assoc.* 2014;3:e001270.

26. Kelly R, Staines A, MacWalter R, et al. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. *J Am Coll Cardiol.* 2002;39:219–224.

27. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. *J Am Coll Cardiol.* 2009;54:2129–2138.

28. Brevetti G, Giugliano G, Brevetti L, et al. Inflammation in peripheral arterial disease. *Circulation.* 2010;122:1862–1875.

29. Yeh CC, Wang HH, Chou YC, et al. High risk of gastrointestinal hemorrhage in patients with epilepsy: a nationwide cohort study. *Mayo Clin Proc.* 2013;88:1091–1098.

30. Lee WJ, Shin JH, Park SY. Relation of Pulmonary Function Impairment and Coronary Artery Calcification by Multi-detector Computed Tomography in Group Exposed to Inorganic Dusts. *Tuberc Respir Dis (Seoul).* 2013;74:56–62.

31. Yoon JH, Choi BS, Shin JH, et al. Association between impaired lung function and coronary artery calcium score in workers exposed to inorganic dust. *Toxicol Environ Health Sci.* 2012;4:139–142.

32. Nemmar A, Nemery B, Hoet PH, et al. Silica particles enhance peripheral thrombosis: key role of lung macrophage-neutrophil cross-talk. *Am J Respir Crit Care Med.* 2005;171:872–879.

33. Nemmar A, Hoet PH, Vandervoort P, et al. Enhanced peripheral thrombogenicity after lung inflammation is mediated by platelet-leukocyte activation: role of P-selectin. *J Thromb Haemost.* 2007;5:1217–1226.